Combining data from the DECLARE and DAPA-CKD trials enables the effect of dapagliflozin to be examined across a spectrum of baseline kidney function. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the post-hoc analysis of the DECLARE and DAPA-CKD data and the significance for clinical practice.
The abstract entitled ‘Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What was the purpose of the post-hoc analysis of the DECLARE and DAPA-CKD data? (0:21)
- What subgroups were evaluated in this study? (1:28)
- What were the findings in the different baseline eGFR and urinary albumin: creatinine ratio groups? (2:59)
- What is the significance of these findings for clinical practice? (5:11)
Disclosures: Filipe Moura has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
